Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

Katrin Haeussler; Xuan Wang; Katherine Winfree; Yulia D'yachkova; Sory Traore; Tarun Puri; Howard H Z Thom; Christos Papagiannopoulos; Maria Nassim; Kaisa Taipale

doi:10.2217/fon-2021-0885

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

Katrin Haeussler
, Xuan Wang
, Katherine Winfree
, Yulia D'yachkova
, Sory Traore
, Tarun Puri
, Howard H Z Thom
, Christos Papagiannopoulos
, Maria Nassim
, Kaisa Taipale^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

5 Citations (Scopus)

170 Downloads (Pure)

Abstract

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm+ advanced NSCLC.

Registration information: PROSPERO ID: CRD42020136247

Original language	English
Pages (from-to)	2007-2028
Number of pages	22
Journal	Future Oncology
Volume	18
Issue number	16
DOIs	https://doi.org/10.2217/fon-2021-0885
Publication status	Published - 21 Feb 2022

Bibliographical note

Funding Information:
This work was sponsored by Eli Lilly & Co., IN, USA. KB Winfree, Y D’yachkova, S Traore, T Puri and K Taipale are employees of Eli Lilly and Company, and KB Winfree, Y D’yachkova, T Puri and K Taipale own stock. K Haeussler, X Wang, C Papagiannopoulos and M Nassim received study funding from Eli Lilly as employees at ICON. Howard Thom’s contribution to this work was funded by Eli Lilly through ICON. He furthermore discloses personal consulting fees from Pfizer Inc, Novartis Pharma AG, Roche Holding AG, and Janssen Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2022 Eli Lilly and Company.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

EGFR positive
network meta-analysis
non-small-cell lung cancer
progression-free survival
systematic literature review
tyrosine kinase inhibitors

Access to Document

10.2217/fon-2021-0885

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Future Science Group at https://doi.org/10.2217/fon-2021-0885. Please refer to any applicable terms of use of the publisher.
Final published version, 2.32 MBLicence: CC BY-NC-ND

Handle.net

Persistent link

Embargoed Document

Full-text PDF (accepted author manuscript)
Accepted author manuscript, 202 KB
Licence: Unspecified
Request copy

Cite this

@article{9dd11d15707f4ddba66f5b5ffbd711b4,

title = "Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis",

abstract = "Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm+ advanced NSCLC. Registration information: PROSPERO ID: CRD42020136247",

keywords = "EGFR positive, network meta-analysis, non-small-cell lung cancer, progression-free survival, systematic literature review, tyrosine kinase inhibitors",

author = "Katrin Haeussler and Xuan Wang and Katherine Winfree and Yulia D'yachkova and Sory Traore and Tarun Puri and Thom, \{Howard H Z\} and Christos Papagiannopoulos and Maria Nassim and Kaisa Taipale",

note = "Funding Information: This work was sponsored by Eli Lilly \& Co., IN, USA. KB Winfree, Y D{\textquoteright}yachkova, S Traore, T Puri and K Taipale are employees of Eli Lilly and Company, and KB Winfree, Y D{\textquoteright}yachkova, T Puri and K Taipale own stock. K Haeussler, X Wang, C Papagiannopoulos and M Nassim received study funding from Eli Lilly as employees at ICON. Howard Thom{\textquoteright}s contribution to this work was funded by Eli Lilly through ICON. He furthermore discloses personal consulting fees from Pfizer Inc, Novartis Pharma AG, Roche Holding AG, and Janssen Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2022 Eli Lilly and Company.",

year = "2022",

month = feb,

day = "21",

doi = "10.2217/fon-2021-0885",

language = "English",

volume = "18",

pages = "2007--2028",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor \& Francis Group",

number = "16",

}

TY - JOUR

T1 - Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

AU - Haeussler, Katrin

AU - Wang, Xuan

AU - Winfree, Katherine

AU - D'yachkova, Yulia

AU - Traore, Sory

AU - Puri, Tarun

AU - Thom, Howard H Z

AU - Papagiannopoulos, Christos

AU - Nassim, Maria

AU - Taipale, Kaisa

N1 - Funding Information: This work was sponsored by Eli Lilly & Co., IN, USA. KB Winfree, Y D’yachkova, S Traore, T Puri and K Taipale are employees of Eli Lilly and Company, and KB Winfree, Y D’yachkova, T Puri and K Taipale own stock. K Haeussler, X Wang, C Papagiannopoulos and M Nassim received study funding from Eli Lilly as employees at ICON. Howard Thom’s contribution to this work was funded by Eli Lilly through ICON. He furthermore discloses personal consulting fees from Pfizer Inc, Novartis Pharma AG, Roche Holding AG, and Janssen Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2022 Eli Lilly and Company.

PY - 2022/2/21

Y1 - 2022/2/21

N2 - Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm+ advanced NSCLC. Registration information: PROSPERO ID: CRD42020136247

AB - Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm+ advanced NSCLC. Registration information: PROSPERO ID: CRD42020136247

KW - EGFR positive

KW - network meta-analysis

KW - non-small-cell lung cancer

KW - progression-free survival

KW - systematic literature review

KW - tyrosine kinase inhibitors

U2 - 10.2217/fon-2021-0885

DO - 10.2217/fon-2021-0885

M3 - Article (Academic Journal)

C2 - 35187947

SN - 1479-6694

VL - 18

SP - 2007

EP - 2028

JO - Future Oncology

JF - Future Oncology

IS - 16

ER -

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this